SCHEMBL29979186

SCHEMBL29979186

Cc1nonc1[C@@]1(CNC(=O)OC(C)(C)C)NC(=O)NC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 6/20 0.35
MMP14 P50281 6/20 0.35
ADAMTS5 Q9UNA0 6/20 0.35
ADAMTS4 O75173 5/20 0.35
MMP2 P08253 5/20 0.35
MMP3 P08254 5/20 0.35
HCRTR2 O43614 1/20 0.34
ADAMTS7 Q9UKP4 8/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
ADAM17 P78536 5/20 0.33
MMP1 P03956 3/20 0.33
MMP7 P09237 3/20 0.33
MMP9 P14780 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALDH1A1 P00352 2/20 0.32
GFER P55789 1/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24927835 1.00 MMP13 (0.35) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL23354542 0.84 ADAMTS4 (0.38) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL29979254 0.82 ADAMTS5 (0.37) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL24927847 0.82 ADAMTS5 (0.37) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL24927822 0.82 ADAMTS7 (0.35) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL29979689 0.82 ADAMTS7 (0.34) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL24927725 0.82 ADAMTS7 (0.34) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL29980101 0.82 ADAMTS7 (0.35) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL24928004 0.79 L3MBTL1 (0.34) MMP13MMP14ADAMTS5ADAMTS4MMP2
SCHEMBL24927849 0.79 ADAMTS7 (0.53) MMP13MMP14ADAMTS5ADAMTS4MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 MMP13 55/4885MMP14 80/4885ADAMTS5 7/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 MMP13 55/4885MMP14 80/4885ADAMTS5 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.